RSS   Newsletter   Contact   Advertise with us

Bruce L.A. Carter joins Biothera board of directors

Staff writer | Eagan, Mn., USA — Biothera, a biotechnology company, announced the appointment of Bruce L.A. Carter to its board of directors.[break]


Dr. Carter has extensive experience in the pharmaceutical industry. He served as President of ZymoGenetics, Inc. from 1988 to 1994 when Novo Nordisk acquired the company. At Novo Nordisk, Dr. Carter was Corporate Executive Vice President and Chief Scientific Officer until 2000 when he led a buyout of ZymoGenetics.

He was named President and Chief Executive Officer of the independent company and led ZymoGenetics’ successful development and commercialization of Recothrom, a recombinant thrombin for use during surgical procedures. Bristol
| February 6, 2014
BiotheraFebruary 6, 2014, Eagan, Mn., USA — Biothera, a biotechnology company, announced the appointment of Bruce L.A. Carter to its board of directors.
Dr. Carter has extensive experience in the pharmaceutical industry. He served as President of ZymoGenetics, Inc. from 1988 to 1994 when Novo Nordisk acquired the company. At Novo Nordisk, Dr. Carter was Corporate Executive Vice President and Chief Scientific Officer until 2000 when he led a buyout of ZymoGenetics.

He was named President and Chief Executive Officer of the independent company and led ZymoGenetics’ successful development and commercialization of Recothrom, a recombinant thrombin for use during surgical procedures. Bristol-Myers Squibb acquired ZymoGenetics in 2008.

More recently, Dr. Carter was Executive Chairman of Immune Design Corp. from 2009 to 2011. He currently serves as a director of several publicly traded companies: Dr. Reddy’s Laboratories Ltd., Enanta Pharmaceuticals, Inc., Regulus Therapeutics, Inc. and Xencor, Inc.

Dr. Carter received a B.Sc. with Honors in Botany from the University of Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth College, University of London.


 LATEST MOVES FROM  


    MORE INSIDE POST